BackSAB Biotherapeutics Overview

SAB Biotherapeutics Long Term Debt

SAB Biotherapeutics's long-term debt is $4.5M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$4.49M
↓ 17.68% YoYΔ $-964424.00 vs prior year quarter

Peer average

Loading

SAB Biotherapeutics Long Term Debt History

Loading

SAB Biotherapeutics vs. peers: Long Term Debt Comparison

Loading

SAB Biotherapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

SAB Biotherapeutics (SABS) FAQ

As of the most recent data (June 2026), SABS shows a long-term debt of $4.5M. That compares with $5.5M in the prior-year period — down 17.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SABS's long-term debt is now $4.5M (was $5.5M) — a 17.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether SAB Biotherapeutics is outperforming or lagging.

Tracking SABS's long-term debt over time shows whether SAB Biotherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $4.5M That compares with $5.5M in the prior-year period — down 17.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has SAB Biotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $4.5M) with ownership activity and broader fundamentals.